Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neuroscience

• Publication date

  2013-08-29

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1016/j.neuroscience.2013.04.058PMID 23660195PMCID PMC3813005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome

  2013cited by this paper
• High MMP‐9 activity levels in fragile X syndrome are lowered by minocycline

  2013cited by this paper
• Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome.

  2012cited by this paper
• Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X Syndrome

  2012cited by this paper
• Activity-Dependent Local Translation of Matrix Metalloproteinase-9

  2012cited by this paper
• Early Intervention Combined with Targeted Treatment Promotes Cognitive and Behavioral Improvements in Young Children with Fragile X Syndrome

  2012cited by this paper
• FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism.

  2011cited by this paper
• Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology

  2011cited by this paper
• Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic‐like responses

  2011cited by this paper
• Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase

  2011cited by this paper
• GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism

  2010cited by this paper
• Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

  2010cited by this paper
• A Novel Target of Action of Minocycline in NGF-Induced Neurite Outgrowth in PC12 Cells: Translation Initiation Factor eIF4AI

  2010cited by this paper
• Dysregulation of mTOR Signaling in Fragile X Syndrome

  2010cited by this paper
• Fragile X and autism: Intertwined at the molecular level leading to targeted treatments

  2010cited by this paper
• Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.

  2010cited by this paper
• Open-label add-on treatment trial of minocycline in fragile X syndrome

  2010cited by this paper
• Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome

  2009cited by this paper
• The State of Synapses in Fragile X Syndrome

  2009cited by this paper
• Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

  2009cited by this paper
• Increased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment

  2009cited by this paper
• Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety

  2009cited by this paper
• Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy.

  2009cited by this paper
• Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately

  2008cited by this paper
• Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome

  2008cited by this paper
• Important role of matrix metalloproteinase 9 in epileptogenesis

  2008cited by this paper
• Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model

  2008cited by this paper
• The role of GSK‐3 in synaptic plasticity

  2008cited by this paper
• Unaltered hormonal response to stress in a mouse model of fragile X syndrome.

  2008cited by this paper
• Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome.

  2008cited by this paper
• FMRP Phosphorylation Reveals an Immediate-Early Signaling Pathway Triggered by Group I mGluR and Mediated by PP2A

  2007cited by this paper
• TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex.

  2007cited by this paper
• The extracellular protease matrix metalloproteinase-9 is activated by inhibitory avoidance learning and required for long-term memory.

  2007cited by this paper
• In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity.

  2007cited by this paper
• Correction of fragile X syndrome in mice.

  2007cited by this paper
• Matrix Metalloproteinase-9 Is Required for Hippocampal Late-Phase Long-Term Potentiation and Memory

  2006cited by this paper
• mRNPs, polysomes or granules: FMRP in neuronal protein synthesis.

  2006cited by this paper
• Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression.

  2006cited by this paper
• Regulation of Eukaryotic Initiation Factor 4E by Converging Signaling Pathways during Metabotropic Glutamate Receptor-Dependent Long-Term Depression

  2006cited by this paper
• Local Protein Synthesis and Spine Morphogenesis: Fragile X Syndrome and Beyond

  2006cited by this paper
• Dose–Response Effect of Tetracyclines on Cerebral Matrix Metalloproteinase-9 after Vascular Endothelial Growth Factor Hyperstimulation

  2006cited by this paper
• Spine architecture and synaptic plasticity.

  2005cited by this paper
• Molecular mechanisms of dendritic spine development and remodeling.

  2005cited by this paper
• Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.

  2005cited by this paper
• Minocycline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia‐induced cerebellar hypoplasia in the Gunn rat

  2005cited by this paper
• Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on.

  2005cited by this paper
• Extracellular Signal-Regulated Protein Kinase Activation Is Required for Metabotropic Glutamate Receptor-Dependent Long-Term Depression in Hippocampal Area CA1

  2004cited by this paper
• Minocycline attenuates nitric oxide-mediated neuronal and axonal destruction in vitro.

  2004cited by this paper
• A phenotypic and molecular characterization of the fmr1‐tm1Cgr Fragile X mouse

  2004cited by this paper
• Minocycline Exerts Multiple Inhibitory Effects on Vascular Endothelial Growth Factor–Induced Smooth Muscle Cell Migration: The Role of ERK1/2, PI3K, and Matrix Metalloproteinases

  2004cited by this paper
• Long‐term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences

  2004cited by this paper
• Activation of the Phosphoinositide 3-Kinase-Akt-Mammalian Target of Rapamycin Signaling Pathway Is Required for Metabotropic Glutamate Receptor-Dependent Long-Term Depression

  2004cited by this paper
• Minocycline prevents glutamate‐induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways

  2004cited by this paper
• The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review.

  2003cited by this paper
• Dendritic spine pathology: cause or consequence of neurological disorders?

  2002cited by this paper
• Morphological changes in dendritic spines associated with long-term synaptic plasticity.

  2001cited by this paper
• Minocycline-induced lupus: clinical features and response to rechallenge.

  2001cited by this paper
• Synaptic regulation of protein synthesis and the fragile X protein

  2001cited by this paper
• Audiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome

  2000cited by this paper
• Dendritic Anomalies in Disorders Associated with Mental Retardation

  2000cited by this paper
• Epilepsy and EEG Findings in Males with Fragile X Syndrome

  1999cited by this paper
• Minocycline-induced autoimmune syndromes: an overview.

  1999cited by this paper
• Biology of the fragile X mental retardation protein, an RNA-binding protein.

  1999cited by this paper
• Dendritic anomalies in disorders associated with mental retardation.

  1999cited by this paper
• Differences in Measures of Exploration and Fear in MHC-Congenic C57BL/6J and B6-H-2K Mice

  1999cited by this paper
• Structure, development, and plasticity of dendritic spines.

  1999cited by this paper
• Purified Recombinant Fmrp Exhibits Selective RNA Binding as an Intrinsic Property of the Fragile X Mental Retardation Protein*

  1998cited by this paper
• Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying

  1995cited by this paper
• The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice

  1994cited by this paper
• Evaluation of marble-burying behavior as a model of anxiety.

  1991cited by this paper
• Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.

  1986cited by this paper
• Adult fragile X syndrome

  1985cited by this paper
• Is the isolated animal a possible model for phobia and anxiety?

  1981cited by this paper
• The “isolation syndrome” in mice

  1973cited by this paper

• Preclinical rodent studies support minocycline as an adjunctive anxiolytic.

  2026cites this paper
• Early rebalancing of neuroinflammatory cascades lastingly rescues prefrontal deficits in a 22q11.2ds model.

  2026cites this paper
• Differential effects of sound repetition rate on auditory cortex development and behavior in fragile X syndrome mouse model.

  2025cites this paper
• Minocycline attenuates panicogenic responses in a CO2-induced panic attack model: a translational approach

  2025cites this paper
• Minocycline inhibits microglial activation and mitigates compulsive and anxiety-like behaviors induced by a high-refined carbohydrate diet in male BALB/c mice

  2025cites this paper
• Combined Treatment with Minocycline and an mGluR5 Antagonist Alters Resting EEG Spectral Power, but Not Sound-Evoked Responses, in a Mouse Model of Fragile X Syndrome

  2025cites this paper
• Behavioral, neurotransmitter and transcriptomic analyses in male and female Fmr1 KO mice

  2024cites this paper
• Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome

  2024cites this paper
• Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome

  2024cites this paper
• EphB2 Signaling Is Implicated in Astrocyte-Mediated Parvalbumin Inhibitory Synapse Development

  2024cites this paper
• An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs

  2024cites this paper
• Matrix metalloproteinase‐9: A magic drug target in neuropsychiatry?

  2023cites this paper
• Minocycline as a potential anxiolytic drug: systematic review and meta-analysis of evidence in murine models

  2023cites this paper
• Molecular mechanisms for targeted treatments in fragile X syndrome

  2023cites this paper
• High-Fat Diet Exacerbates Autistic-Like Restricted Repetitive Behaviors and Social Abnormalities in CC2D1A Conditional Knockout Mice

  2022cites this paper
• Acute and Repeated Administration of NLX-101, a Selective Serotonin-1A Receptor Biased Agonist, Reduces Audiogenic Seizures in Developing Fmr1 Knockout Mice.

  2022cites this paper
• Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome

  2022cites this paper
• Influence of Gestational Chlorpyrifos Exposure on ASD-like Behaviors in an fmr1-KO Rat Model

  2022cites this paper
• Targeted Therapy of Cognitive Deficits in Fragile X Syndrome

  2022cites this paper
• EEG as a translational biomarker and outcome measure in fragile X syndrome

  2022cites this paper
• Reconnoitering the transformative journey of minocycline from an antibiotic to an antiepileptic drug.

  2022cites this paper
• Sustained correction of hippocampal neurogenic and cognitive deficits after a brief treatment by Nutlin-3 in a mouse model of fragile X syndrome

  2022cites this paper
• The Use of Peptides in the Treatment of Fragile X Syndrome: Challenges and Opportunities

  2021cites this paper
• Activity and Function of the PRMT8 Protein Arginine Methyltransferase in Neurons

  2021cites this paper
• Neural Correlates of Auditory Hypersensitivity in Fragile X Syndrome

  2021cites this paper
• Loss of CC2D1A in Glutamatergic Neurons Results in Autistic-Like Features in Mice

  2021cites this paper
• An “Omic” Overview of Fragile X Syndrome

  2021cites this paper
• An ‘’Omic’’ Overview of Fragile X Syndrome

  2021cites this paper
• Dietary rescue of adult behavioral deficits in the Fmr1 knockout mouse

  2021cites this paper
• Channelopathies in fragile X syndrome

  2021cites this paper
• Neural Mechanisms Underlying Repetitive Behaviors in Rodent Models of Autism Spectrum Disorders

  2021cites this paper
• Developmental studies in fragile X syndrome

  2020cites this paper
• Acute pharmacological inhibition of matrix metalloproteinase‐9 activity during development restores perineuronal net formation and normalizes auditory processing in Fmr1 KO mice

  2020cites this paper
• Pharmacological treatments for fragile X syndrome based on synaptic dysfunction.

  2020cites this paper
• Quantitative EEG Analysis in Angelman Syndrome: Candidate Method for Assessing Therapeutics

  2020cites this paper
• Abnormal development of auditory responses in the inferior colliculus of a mouse model of Fragile X Syndrome.

  2020cites this paper
• Minocycline in neurodegenerative and psychiatric diseases: An update

  2020cites this paper
• Minocycline Treatment Reverses Sound Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome

  2020cites this paper
• Autism spectrum disorder

  2020cites this paper
• Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome

  2020cites this paper
• The Protein Arginine Methyltransferase PRMT8 and Substrate G3BP1 Control Rac1-PAK1 Signaling and Actin Cytoskeleton for Dendritic Spine Maturation.

  2020cites this paper
• Resolving and Rescuing Developmental Miswiring in a Mouse Model of Cognitive Impairment

  2019cites this paper
• Repurposing available drugs for neurodevelopmental disorders: The fragile X experience

  2019cites this paper
• Developmental Changes in EEG Phenotypes in a Mouse Model of Fragile X Syndrome.

  2019cites this paper
• Minocycline mitigates the effect of neonatal hypoxic insult on human brain organoids

  2019cites this paper
• Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9.

  2019influential citation
• Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome.

  2019cites this paper
• Deletion of Fmr 1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular , EEG , and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome

  2019cites this paper
• Audiogenic Seizures in the Fmr1 Knock-Out Mouse Are Induced by Fmr1 Deletion in Subcortical, VGlut2-Expressing Excitatory Neurons and Require Deletion in the Inferior Colliculus

  2019cites this paper
• The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders

  2018cites this paper
• Development of Structural and Functional Abnormalities Underlying Auditory Hypersensitivity in a Mouse Model of Fragile X Syndrome

  2018cites this paper
• Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome.

  2018cites this paper
• Sensory Processing Phenotypes in Fragile X Syndrome

  2018cites this paper
• Chronic minocycline treatment improves hippocampal neuronal structure, NMDA receptor function, and memory processing in Fmr1 knockout mice.

  2018cites this paper
• Inhibition in Executive Function Neurocircuits in an Autism Model, and Human Neocortex

  2018cites this paper
• Microglia inhibition rescues developmental hypofrontality in a mouse model of mental illness

  2018cites this paper
• Critical Period Inhibition of NKCC1 Rectifies Synapse Plasticity in the Somatosensory cortex and Restores Adult Tactile Response Maps in Fragile X Mice

  2018cites this paper
• Effects of minocycline and doxycycline against terbutaline induced early postnatal autistic changes in albino rats.

  2018cites this paper
• Potential Involvement of Impaired BKCa Channel Function in Sensory Defensiveness and Some Behavioral Disturbances Induced by Unfamiliar Environment in a Mouse Model of Fragile X Syndrome

  2018cites this paper
• Minocycline Attenuates Stress-Induced Behavioral Changes via Its Anti-inflammatory Effects in an Animal Model of Post-traumatic Stress Disorder

  2018cites this paper
• Matrix Metalloproteinases in Fragile X Syndrome

  2017cites this paper
• Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome

  2017cites this paper
• Behavioural and molecular characterisation of mice haploinsufficient for Map2k7, a schizophrenia risk gene

  2017cites this paper
• Fragile X targeted pharmacotherapy: lessons learned and future directions

  2017cites this paper
• Secreted tissue inhibitor of matrix metalloproteinase restricts trans-synaptic signaling to coordinate synaptogenesis

  2017cites this paper
• Cellular and synaptic pathophysiology in a rat model of Fragile X syndrome

  2017cites this paper
• Review of targeted treatments in fragile X syndrome.

  2016cites this paper
• Chronic minocycline treatment improves social recognition memory in adult male Fmr1 knockout mice.

  2016cites this paper
• Developmental minocycline treatment reverses the effects of neonatal immune activation on anxiety- and depression-like behaviors, hippocampal inflammation, and HPA axis activity in adult mice.

  2016cites this paper
• Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective.

  2016cites this paper
• Autism Spectrum Disorder: Genes to Pathways to Circuits

  2016cites this paper
• Neuronal mechanisms and circuits underlying repetitive behaviors in mouse models of autism spectrum disorder

  2016cites this paper
• Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in Fragile X Syndrome

  2016cites this paper
• Gut-to-Brain Axis in Autism Spectrum Disorders: Central Role for the Microbiome.

  2016cites this paper
• A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders

  2015cites this paper
• Dendritic spine abnormalities in a mouse model of Fragile X syndrome

  2015cites this paper
• Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

  2015cites this paper
• Abnormal neuronal morphology and neurochemistry in the auditory brainstem of Fmr1 knockout rats.

  2015cites this paper
• Altered Microglia in the Amygdala Are Involved in Anxiety-related Behaviors of a Copy Number Variation Mouse Model of Autism.

  2015cites this paper
• Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes

  2015cites this paper
• Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models

  2014cites this paper
• Neurodevelopmental and neuropsychiatric disorders

  2014cites this paper
• Anxiety, hyperactivity and stereotypy in a zebrafish model of fragile X syndrome and autism spectrum disorder.

  2014cites this paper
• The promising trajectory of autism therapeutics discovery.

  2014cites this paper
• Fragile X syndrome neurobiology translates into rational therapy.

  2014cites this paper
• Degraded speech sound processing in a rat model of fragile X syndrome.

  2014cites this paper
• Genetic Removal of Matrix Metalloproteinase 9 Rescues the Symptoms of Fragile X Syndrome in a Mouse Model

  2014cites this paper
• Modeling fragile X syndrome in the Fmr1 knockout mouse.

  2014cites this paper
• Microglial Abnormalities in the Pathophysiology of

  2014cites this paper
• From FMRP Function to Potential Therapies for Fragile X Syndrome

  2014cites this paper
• Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us

  2014cites this paper
• Auditory Processing in Fragile X Syndrome

  2014cites this paper
• Translational endpoints in fragile X syndrome.

  2014cites this paper
• Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes

  2014cites this paper
• Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model

  2013cites this paper
• Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome.

  2012cites this paper